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mane replacement therapy (HRT), and cancer screening.
HRT is effective for treating the symptoms of acute
menopause, and it may prevent some chronic health
problems associated with growing older. However, HRT
may increase the risks for other diseases.
OBJECTIVE: The purpose of this study was to estimate
the level of health care use and costs incurred by post-
menopausal women for conditions that have been associ-
ated with HRT.
METHODS: National health care survey and discharge
data were used to estimate health care use by women age
45 and older for cardiovascular disease, osteoporosis,
breast cancer, uterine cancer, and deep-vein thrombosis/
pulmonary embolism. The databases used were the
Healthcare Utilization Project-S, National Ambulatory
Medical Care Survey, National Hospital Ambulatory
Medical Care Survey, National Nursing Home Survey,
and National Home and Hospice Care Survey. Clinical
Classification for Health Policy Research codes were used
to identify patients whose primary diagnosis or procedure
corresponded with the above conditions. National
weights were used to estimate resource use. Treatment
costs were estimated using cost-to-charge ratios or Medi-
care Fee Schedule to calculate costs of individual proce-
dures.
RESULTS: For each of the five conditions, resource use
and costs are reported for hospitalization, outpatient,
nursing home, and home health care services. Resource
use and costs are also reported by age and race/ethnicity.
CONCLUSION: Results of the study may be used to esti-
mate the burden of disease for conditions commonly af-
fecting postmenopausal women and to provide data for
cost-effectiveness models comparing newly developed
drugs to existing HRTs.
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OBJECTIVE: To isolate the cost of bone fracture to a
Medicaid/Medicare payor for an osteoporosis-prone pop-
ulation.
SUBJECTS: Claims data for Georgia Medicaid eligibles
from 1992 through 1994 were obtained. Recipients meet-
ing the following inclusion criteria were retained for anal-
ysis: age 250 years, female, claim with an ICD9 code in-
dicative of fracture in 1993, 12 months of contiguous
eligibility immediately prior to and after first fracture
claim. Recipients were stratified based upon site of frac-
ture (femur/other fracture site).
METHODS: Amounts paid by Medicaid and Medicare
were proxies for direct medical costs. Per recipient per
month costs were disaggregated by category of service
(hospital, nursing home, physician, prescription, miscella-
neous) for each of the 24 months of the study. Inter-
rupted time series models were estimated to isolate the in-
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cremental change in cost due to fracture, with terms
controlling for pre-existing trend, run-in costs, and any
autoregressive errors.
RESULTS: A total of 765 subjects met inclusion criteria,
with 226 femur fracture patients. All times series models
estimated are significant, with R-squares ranging from
0.90 to 0.98. Average total cost temporarily increased
$1,120 and $1,091 for the month of femur and other
fracture, respectively. Observed cost increases returned to
baseline trend levels within three months after fracture.
Likewise, costs disagregated by category of service tem-
porarily increased with fracture, except nursing home
costs, which permanently increased after fracture.
CONCLUSION: Only nursing home costs increased per-
sistently over a 12-month period ensuing fracture; all
other costs increased but quickly returned to baseline
trend. The incremental direct total cost of any type of
fracture is less than $2,000. This is in contrast to the
$13,396 in outlays by Medicaid and Medicare the year
after fracture for the average fracture patient.
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Osteoporosis is a chronic degenerative disease with con-
centrated prevalence in the most rapidly growing segment
of the population, the elderly. Its clinical and economic
consequences are substantial. This study assesses the cost-
effectiveness of two gold standard therapeutic approaches
to reducing the impact of related fractures.
OBJECTIVES: To determine the cost-effectiveness ratios
of the two therapeutic approaches. To model the cohort
progression through the Markov states.
METHODS: Using published literature values, a Markov
model was constructed. The model depicts a cohort of
1,000 women progressing from age 50 to 90 years or
death, whichever comes first. The hormone therapy alter-
native includes calcium supplementation as part of the
regimen. The model accounts for the following confound-
ers: age dependent rate of death, predisposition to subse-
quent fracture, and the cardioprotective effect of hor-
mone therapy. Sensitivity analysis was conducted on all
relevant variables to assess the robustness of the findings.
The primary outcome of interest was cost per fracture
avoided. Additionally, Markov analysis of the model re-
ports the distribution of women across each Markov
state.
RESULTS: The study revealed that hormone therapy is
more cost-effective than calcium therapy. Cost-effective-
ness ratios for the two alternatives were $43,729.82 and
$87,003.53 per fracture avoided for hormone therapy
and calcium therapy, respectively. The incremental cost-
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effectiveness ratio was $32,828.60, indicating the cost of
avoiding each additional fracture using the less desirable
calcium therapy. The cardioprotective effect of hormone
therapy accounted for nearly 3 additional years of life for
each woman on therapy.
CONCLUSIONS: Hormone replacement therapy in con-
junction with calcium supplementation is far more cost-
effective than calcium supplementation alone.
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Post-menopausal hormone replacement therapies (HRT)
represent a significant long-term pharmacological treat-
ment that is associated with multiple beneficial clinical
outcomes. However, HRT is associated with a significant
reduction in patient compliance over time.
OBJECTIVE: To determine the impact of periodically
mailed patient educational materials on HRT compliance.
METHODS: Using centralized pharmacy records from a
managed-care organization, both retrospective baseline
(12 months preceding mailings) and prospective (12
months following mailings) compliance indices were ana-
lyzed for three cohorts of patients: Cohort A = patients
who were receiving material prior to program initiation;
Cohort B = patients who were offered material but de-
clined; and Cohort C = patients who had not previously
received material but elected to do so during the study pe-
riod. Compliance indices included assessment of MED-
INT (number of days of medication), MED-TOT (total
medication) and MED-OUT (days without medication).
Patients were identified as "compliant" if they had a
MED-TOT >75% or a MED-OUT <25%.
RESULTS: 584 patients (Cohort A = 149, Cohort B =
245, and Cohort C = 190) were included in analyses.
During the retrospective baseline period, all three cohorts
had statistically similar compliance indices. Analyses of
data collected during the prospective period indicated
that, compared to Cohort B, significant (p < 0.01) be-
tween-group improvements in each of the compliance in-
dices were observed. Furthermore, the greatest overall
improvements from baseline were observed in Cohort C,
and Cohort C demonstrated a significant (p < 0.01) in-
crease in number of "compliant" patients compared to
Cohort B.
CONCLUSION: These results suggest that educational
material significantly improves patient compliance, and
the effect can be directly observed by assessing central-
ized pharmacy records.
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OBJECTIVES: To study differences among two regimens
of estrogen/progestin replacement therapy in post-meno-
pausal women with respect to quality of life, pharrnacoeco-
nomics, bleeding pattern, compliance, and safety profile.
METHODS: A 12-center, randomized, comparative dose
study was conducted in 183 women (mean age: 53.9
years) randomized to one of two treatment arms:
Prometrium" 200 mg (n = 90) or Provera® 5 mg (n =
93) administered in a single daily dose for 14 days in a
3D-day cycle. All patients received 0.625 mg Premarin®
for 25 of the 30 days. Quality of life was measured by the
Nottingham Health Profile (NHP), Woman's Health
Questionnaire (WHQ), and Short Form 36 (SF-36).
RESULTS: Improvements in climacteric symptoms were
observed between baseline and month 9 within both
groups. All domains within the NHP and WHQ im-
proved significantly for both patient groups (p < 0.008),
and greater improvements were observed for Prometrium
patients in the Menstrual Problems and Cognitive Diffi-
culties domains of the WHQ. While Prometrium patients
reported an improvement in the Menstrual Problems do-
main, Provera patients reported a worsening. The num-
ber of cycles with bleeding was significantly higher for
the Provera patients (p = 0.001). Average nine-month so-
cietal menopausal costs/patient were $367 ± $120 (Cdn)
for Prometrium patients and $360 ± $369 (Cdn) for
Provera patients (not statistically significant). Although
costs were variable, offsetting savings for Prometrium pa-
tients were observed in out-of-pocket expenses and
missed time from work.
CONCLUSIONS: This study highlights important qual-
ity of life and cost aspects of Prometrium and Provera use
that may impact longer term compliance when patients
use Prometrium + Premarin regimens.
